Heparine Leo (Heparin Sodium)

Heparine Leo is indicated for several clinical situations where anticoagulation is required.

• Prevention and treatment of venous thromboembolism, including deep‑vein thrombosis and pulmonary embolism.
• Prophylaxis of deep‑vein thrombosis in patients undergoing orthopedic or general surgery.
• Anticoagulation during cardiac surgery procedures such as cardiopulmonary bypass.
• Management of acute coronary syndrome when rapid anticoagulation is needed.
• Use as an adjunct in extracorporeal circulation or dialysis circuits to maintain circuit patency.

Adverse reactions to Heparine Leo can vary in frequency and severity; they are typically categorized as common or serious.

Common

• Minor bleeding at the injection site or bruising.
• Small hematomas.
• Mild nausea or vomiting.
• Transient elevation of liver enzymes.
• Localized pain at the injection site.
• Transient hypotension.

Serious

• Major hemorrhage, including internal bleeding.
• Heparin‑induced thrombocytopenia (HIT).
• Allergic reactions such as urticaria, angioedema, or anaphylaxis.

When prescribing Heparine Leo, clinicians should evaluate patient‑specific factors and monitor for potential complications.

• Assess baseline coagulation parameters and platelet count before initiating therapy.
• Adjust dose in patients with renal or hepatic impairment.
• Use caution in individuals with a history of heparin‑induced thrombocytopenia.
• Monitor for signs of bleeding, especially in surgical or trauma patients.
• Avoid use during pregnancy unless benefits outweigh risks; category B indicates limited data.
• Consider age‑related dosing adjustments for elderly patients.
• Review concomitant use of other anticoagulants or antiplatelet agents.

Heparine Leo may interact with other medications that affect hemostasis or platelet function, requiring careful management.

Avoid

• Concurrent use with other parenteral anticoagulants (e.g., direct thrombin inhibitors) due to additive bleeding risk.
• Combination with systemic thrombolytic agents (e.g., alteplase) without dose adjustment.
• Simultaneous administration of high‑dose aspirin or non‑steroidal anti‑inflammatory drugs (NSAIDs) that increase bleeding tendency.

Use with caution

• Co‑administration with oral anticoagulants such as warfarin; monitor INR closely.
• Use alongside antiplatelet drugs (clopidogrel, ticagrelor); observe for enhanced hemorrhagic effects.
• Concomitant therapy with drugs that may cause thrombocytopenia (e.g., quinine, carbamazepine).